CJC-1295 Ipamorelin Stack: Dosing, Timing and Cycle Length

Why Does Stacking CJC-1295 with Ipamorelin Release More Growth Hormone Than Either Peptide Alone?

CJC-1295 binds to the GHRH receptor. Ipamorelin binds to a different receptor, the ghrelin receptor (GHSR-1a). Both receptors sit on the same pituitary cell. Turning on both at once roughly doubles the growth hormone signal, compared to using either one alone. The two receptors use different chemical paths inside the cell. These paths boost each other's effect.

What Receptor Does CJC-1295 Actually Bind, and What Happens After It Docks?

CJC-1295 is a modified version of GHRH (growth hormone releasing hormone). GHRH is the body's own signal that tells the pituitary gland to release growth hormone. CJC-1295 binds to the GHRH receptor on cells called somatotrophs. These cells are the growth hormone factories inside the pituitary gland. This binding switches on an enzyme called adenylate cyclase. The enzyme raises a messenger molecule called cAMP inside the cell. Rising cAMP tells the cell to release stored growth hormone into the blood. In Teichman et al. 2006, healthy adults got one CJC-1295-with-DAC injection. Their plasma growth hormone jumped 2 to 10-fold for 6 or more days. IGF-1 (a marker that shows growth hormone activity) rose 1.5 to 3-fold for 9 to 11 days. A follow-up study found that growth hormone still came out in pulses. It did not rise as one flat wave, even during this longer stimulation. Ionescu & Frohman 2006

What Receptor Does Ipamorelin Target, and Why Does It Skip the Cortisol Spike?

Ipamorelin works through a completely different lock and key. It binds the ghrelin receptor, also called GHSR-1a. This receptor sits on the same somatotroph cells [growth hormone producing cells]. But it triggers a separate chain reaction inside the cell. This reaction uses calcium instead of cAMP. Older compounds in this class, like GHRP-6 and GHRP-2, also hit this receptor. But they spill over into cortisol and prolactin release. Ipamorelin does not do this. Raun et al. 1998 found that ipamorelin released growth hormone with a potency similar to GHRP-6. Even at doses 200 times its effective threshold, it did not meaningfully raise ACTH or cortisol. This clean profile is why ipamorelin, not an older GHRP, became the default partner for CJC-1295.

Why Two Receptors on the Same Cell Beat One

Here is the part most protocol pages skip. The GHRH receptor and the ghrelin receptor do not compete for the same job. They do two different jobs. Both jobs end in growth hormone release. Cell studies tested both receptors side by side. Activating them together produced a cAMP signal [a chemical messenger inside cells]. This signal was roughly double what GHRH-receptor activation produced alone. Cunha & Mayo 2002 A separate modelling study used real human and rodent (rat) pulse data. It found that ghrelin-receptor activity boosts GHRH's own release from the hypothalamus. At the same time, it weakens the inhibitory brake called somatostatin. Farhy et al. 2005 Somatostatin is the body's off switch for growth hormone. Human data from patients with a non-working GHRH receptor showed something clear. Somatostatin turning off sets the timing of growth hormone pulses. GHRH signal strength sets the size of each pulse. Roelfsema et al. 2001 Stack CJC-1295 and ipamorelin together and you pull both levers. You get more GHRH-driven pulse size and less somatostatin brake. This is the real reason this pairing, not either compound alone, became the reference stack in this space.

Does Combining Them Break the Body's Natural GH Rhythm?

No. This detail separates a GHRH/GHRP pairing [two types of growth hormone triggers] from injecting growth hormone itself. Outside growth hormone [exogenous growth hormone] floods your system. It shuts down your body's own production. This happens through negative feedback, meaning your body senses too much and stops making more. CJC-1295 and ipamorelin work differently. They act upstream, before growth hormone is made. They tell your pituitary gland to release its own stored growth hormone in pulses. This adds to the natural somatostatin/GHRH rhythm [your body's normal hormone cycle] that runs at night and after training. A 2006 study looked at this pulse pattern. It found growth hormone stayed pulse-shaped even with steady CJC-1295 use. It did not flatten into one constant level. Ionescu & Frohman 2006 This is a key difference: an upstream signal versus a downstream replacement. This is also why researchers usually discuss this class differently from exogenous hormone use. For more, see our breakdown of growth hormone secretagogues vs HGH.

No-DAC vs DAC: How Half-Life Changes Which Signal You're Actually Running

CJC-1295 comes in two forms. These two forms send different signals to the GHRH receptor [growth hormone releasing hormone receptor]. This is not just about different injection schedules.

No-DAC clears the body in roughly the same time as ipamorelin. That's exactly why the two are usually drawn into the same syringe. Their receptor activation windows line up. Both hit the somatotroph [the pituitary cell that makes growth hormone] at close to the same moment. DAC changes this pattern. It releases slowly over time. Ipamorelin still gets dosed daily on its own schedule. But CJC-1295 with DAC keeps GHRH-receptor activity elevated in the background for most of the week.

What Does This Mechanism Actually Mean for Sleep, Recovery, and Body Composition?

Growth hormone's biggest natural pulse of the day happens during deep sleep. A pulsatile GHRH/GHRP protocol dosed before bed is designed to land inside that window, not override it. Most research protocols time the no-DAC/ipamorelin pairing 20 to 30 minutes before sleep. They also call for an empty stomach. Here's why: circulating glucose and insulin blunt the GH pulse. Food nearby can blunt the exact mechanism you're trying to use. The receptor-level synergy described above also explains something else. People report faster perceived recovery and better sleep depth on this stack. This happens compared to either compound run solo. That reported effect lines up with the amplified cAMP and reduced somatostatin tone covered earlier. Still, most of the day-to-day recovery reporting is anecdotal rather than from controlled trials.

What's the Standard CJC-1295 + Ipamorelin Dosing Protocol?

Once you understand why the receptors synergize, the dosing logic is simple to follow.

• Ipamorelin: 100-300mcg subcutaneous per injection.
• CJC-1295 (no-DAC): 100mcg subcutaneous, same syringe as ipamorelin.
• Frequency: 1-3 times daily, most often post-workout and pre-bed.
• CJC-1295 with DAC alternative: Take 1-2mg once or twice a week. Keep dosing ipamorelin daily.

Most dosing mistakes happen during reconstitution [mixing the powder with liquid], not during the injection itself. Our reconstitution mg/ml chart walks you through the exact math. It shows you how to turn a vial into the right syringe volume. You can find full dosing details in our CJC-1295 complete guide and ipamorelin complete guide. If you're sourcing either compound, check our recommended sources. Don't trust marketplace listings that skip purity documentation.

How Long Should You Run the Stack Before Taking a Break?

Most protocols run 8-12 weeks on, then take a 4-week break. The reasoning behind this structure matters more than the numbers might suggest. Somatotroph sensitivity [how well growth hormone cells respond to signals] needs a periodic reset. The IGF-1 feedback loop also needs this reset. A scheduled pause does something else too. It gives you a clean read on your results. You can see if the sleep, recovery, or body composition changes you wanted are actually happening.

What Do the Human Safety Data Actually Show?

Human data on this exact combination is limited, but the individual-compound data is not thin. The Teichman trial ran two randomized, placebo-controlled, double-blind ascending-dose studies. These studies lasted 28 and 49 days, in adults aged 21 to 61. Researchers reported no serious adverse reactions tied to CJC-1295 with DAC. Teichman et al. 2006 Ipamorelin's selectivity profile is low cortisol and prolactin spillover, even at very high doses. This was established in controlled animal and cell studies, not anecdote. Raun et al. 1998 For a full breakdown of reported side effects and who should avoid this pairing entirely, read our CJC-1295 side effects and safety guide. This content is for educational purposes only. These compounds are intended for research use. Nothing here replaces a conversation with a qualified clinician before you act on any of it.

Frequently Asked Questions

What is the minimum effective dose if my only goal is better sleep and recovery, not muscle gain?

A safe way to start is ipamorelin alone. Use 100-150mcg under the skin (subcutaneous) before bed. Don't add CJC-1295 yet. This lets you test one hormone signal at a time: the ghrelin-receptor pathway. It shows how your sleep and recovery respond to just this one signal. It also stops you from stacking two receptor signals before you know how your body handles one. If you add CJC-1295 later, start with the no-DAC form. Use a low dose of 50-100mcg. Don't jump straight into the full combined protocol.

How do I come off CJC-1295 and ipamorelin? Is there a tapering protocol?

GHRH and GHRP-class peptides work upstream of the pituitary. This is different from exogenous growth hormone. Because of this, they do not shut down your own hormone axis the way replacement hormone can. There is no published pituitary-suppression pattern tied to stopping this pairing. No formal taper is required mechanistically. In practice, some people report a temporary dip in sleep depth and perceived recovery quality in the first week or two off. This likely reflects the loss of the added GHRH/GHSR pulse, not any withdrawal effect. Coming off gradually is a reasonable approach if you want to track that transition rather than stop cold. To do this, drop to ipamorelin-only for a week before stopping entirely.

Do CJC-1295 and ipamorelin actually need to be injected together?

They don't have to be in the same syringe. But same-syringe dosing is standard practice. Why? Their clearance windows overlap closely. This means both peptides hit the receptor at almost the same moment. That's when the synergy described above actually happens.

Is ipamorelin alone as effective as the full stack?

Ipamorelin alone still turns on the ghrelin receptor [a hormone switch in the gut and brain]. This releases growth hormone. But it misses one extra piece: the GHRH-receptor signal. That signal creates the roughly doubled cAMP response [a chemical messenger inside cells]. You get this boost only when both pathways fire together.

Why is CJC-1295 no-DAC preferred over DAC for this specific stack?

No-DAC has a short half-life [the time it takes for half the dose to clear the body]. This matches ipamorelin's own clearance time. Together, they keep growth hormone release happening in pulses. This is more natural than a flat, constant rise.

Does this stack raise cortisol or blood sugar?

Ipamorelin only targets specific receptors [receptor selectivity]. This means it does not raise cortisol much at standard research doses. Growth hormone secretagogues (substances that trigger growth hormone release) can briefly change blood sugar levels. If you have a metabolic condition, talk to a qualified clinician before you start.